# DAFTAR PUSTAKA

Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clinical Journal of the American Society of Nephrology*, *12*(12), 2032–2045. https://doi.org/10.2215/CJN.11491116

AlSahow, A., Bulbanat, B., Alhelal, B., Alhumoud, K., Alkharaza, A., Alotaibi, T., Alrajab, H., Alyousef, A., & Hadi, F. (2024). Management of hyperkalemia: Expert consensus from Kuwait – a Modified Delphi Approach. *International Journal of Nephrology and Renovascular Disease*, *Volume 17*, 227–240. https://doi.org/10.2147/IJNRD.S476344

Arnold, R., Pianta, T. J., Pussell, B. A., Kirby, A., O'Brien, K., Sullivan, K., Holyday, M., Cormack, C., Kiernan, M. C., & Krishnan, A. V. (2017). Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. *Clinical Journal of the American Society of Nephrology*, *12*(10), 1569–1577. https://doi.org/10.2215/cjn.00670117

Ávila, M., Mora Sánchez, M. G., Bernal Amador, A. S., & Paniagua, R. (2025). The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice. *Biomolecules*, *15*(1), 41. https://doi.org/10.3390/biom15010041

Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., Carrero, J., & Grams, M. E. (2017). Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. *Journal of the American Heart Association*, *6*(7), e005428. https://doi.org/10.1161/JAHA.116.005428

Beccari, M., & Meaney, C. (2017). Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: An evidence-based review. *Core Evidence*, *Volume 12*, 11–24. https://doi.org/10.2147/ce.s129555

Bianchi, S., Aucella, F., De Nicola, L., Genovesi, S., Paoletti, E., & Regolisti, G. (2019). Management of hyperkalemia in patients with kidney disease: A position paper endorsed by the Italian Society of Nephrology. *Journal of Nephrology*, *32*(4), 499–516. https://doi.org/10.1007/s40620-019-00617-y

Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., Ahmadian, E., Al-Aly, Z., Alipour, V., Almasi-Hashiani, A., Al-Raddadi, R. M., Alvis-Guzman, N., Amini, S., Andrei, T., Andrei, C. L., … Vos, T. (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*, *395*(10225), 709–733. https://doi.org/10.1016/S0140-6736(20)30045-3

Burnier, M., & Damianaki, A. (2023). Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. *Circulation Research*, *132*(8), 1050–1063. https://doi.org/10.1161/CIRCRESAHA.122.321762

*Chronic Kidney Disease—StatPearls—NCBI Bookshelf*. (n.d.).

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., Palmer, B. F., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., Pecoits-Filho, R., Ashuntantang, G. E., Bakker, S. J. L., Bakris, G. L., Bhandari, S., … Wingo, C. S. (2020). Potassium homeostasis and management of dyskalemia in kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, *97*(1), 42–61. https://doi.org/10.1016/j.kint.2019.09.018

Collins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017). Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. *American Journal of Nephrology*, *46*(3), 213–221. https://doi.org/10.1159/000479802

Dai, D., Sharma, A., Alvarez, P. J., & Woods, S. D. (2022). Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: A retrospective observational cohort study using association rule mining. *Journal of Multimorbidity and Comorbidity*, *12*, 26335565221098832. https://doi.org/10.1177/26335565221098832

DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (Eds.). (2017). *Pharmacotherapy: A pathophysiologic approach* (Tenth edition). McGraw-Hill Education.

Doumani, G., Theofilis, P., Vordoni, A., Thymis, V., Liapis, G., Smirloglou, D., & Kalaitzidis, R. G. (2025). Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible? *International Journal of Molecular Sciences*, *26*(17), 8224. https://doi.org/10.3390/ijms26178224

Drawz, P. E., Babineau, D. C., & Rahman, M. (2012). Metabolic Complications in Elderly Adults with Chronic Kidney Disease. *Journal of the American Geriatrics Society*, *60*(2), 310–315. https://doi.org/10.1111/j.1532-5415.2011.03818.x

Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009). The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. *Archives of Internal Medicine*, *169*(12), 1156. https://doi.org/10.1001/archinternmed.2009.132

Ferreira, J. P., Rossignol, P., Machu, J.-L., Sharma, A., Girerd, N., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., Hillege, H. L., Lang, C. C., Ter Maaten, J. M., Metra, M., Ng, L., Ponikowski, P., Samani, N. J., Van Veldhuisen, D. J., Zwinderman, A. H., Voors, A., & Zannad, F. (2017). Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF. *European Journal of Heart Failure*, *19*(10), 1284–1293. https://doi.org/10.1002/ejhf.900

Fishbane, S., & Spinowitz, B. (2018). Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. *American Journal of Kidney Diseases*, *71*(3), 423–435. https://doi.org/10.1053/j.ajkd.2017.09.026

Fradisa, L., & Kartika, K. (2025). *Edukasi Dini Kesehatan Ginjal dan Metabolit Untuk Pencegahan Penyakit Ginjal Kronis*. *3*.

Goutorbe, P., Montcriol, A., Lacroix, G., Bordes, J., Meaudre, E., & Souraud, J.-B. (2011). Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate without Sorbitol. *Annals of Pharmacotherapy*, *45*(2), 278–278. https://doi.org/10.1345/aph.1m547

Harel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J., & Bell, C. M. (2013a). Gastrointestinal Adverse Events with Sodium Polystyrene Sulfonate (Kayexalate) Use: A Systematic Review. *The American Journal of*

*Medicine*, *126*(3), 264.e9-264.e24. https://doi.org/10.1016/j.amjmed.2012.08.016

Harel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J., & Bell, C. M. (2013b). Gastrointestinal Adverse Events with Sodium Polystyrene Sulfonate (Kayexalate) Use: A Systematic Review. *The American Journal of Medicine*, *126*(3), 264.e9-264.e24. https://doi.org/10.1016/j.amjmed.2012.08.016

Hunter, R. W., & Bailey, M. A. (2019). Hyperkalemia: Pathophysiology, risk factors and consequences. *Nephrology Dialysis Transplantation*, *34*(Supplement_3), iii2–iii11. https://doi.org/10.1093/ndt/gfz206

Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Gutiérrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., … Levey, A. S. (2021). New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *New England Journal of Medicine*, *385*(19), 1737–1749. https://doi.org/10.1056/NEJMoa2102953

Jadoul, M., Aoun, M., & Masimango Imani, M. (2024). The major global burden of chronic kidney disease. *The Lancet Global Health*, *12*(3), e342–e343. https://doi.org/10.1016/s2214-109x(24)00050-0

Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation*, *143*(11), 1157–1172. https://doi.org/10.1161/CIRCULATIONAHA.120.050686

Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. *The Lancet*, *398*(10302), 786–802. https://doi.org/10.1016/S0140-6736(21)00519-5

Kamel, K. S., Schreiber, M., & Halperin, M. L. (2018). Renal potassium physiology: Integration of the renal response to dietary potassium depletion. *Kidney International*, *93*(1), 41–53. https://doi.org/10.1016/j.kint.2017.08.018

Kanda, E., Kashihara, N., Kohsaka, S., Okami, S., & Yajima, T. (2020). Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based

Cohort Study in Japan. *Kidney Medicine*, *2*(6), 742-752.e1. https://doi.org/10.1016/j.xkme.2020.09.003

Kashihara, N., Kohsaka, S., Kanda, E., Okami, S., & Yajima, T. (2019). Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. *Kidney International Reports*, *4*(9), 1248–1260. https://doi.org/10.1016/j.ekir.2019.05.018

Kim, G.-H. (2019). Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease. *Electrolytes & Blood Pressure*, *17*(1), 1. https://doi.org/10.5049/ebp.2019.17.1.1

Kovesdy, C. P. (2015). Management of Hyperkalemia: An Update for the Internist. *The American Journal of Medicine*, *128*(12), 1281–1287. https://doi.org/10.1016/j.amjmed.2015.05.040

Lepage, L., Dufour, A.-C., Doiron, J., Handfield, K., Desforges, K., Bell, R., Vallée, M., Savoie, M., Perreault, S., Laurin, L.-P., Pichette, V., & Lafrance, J.-P. (2015). Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. *Clinical Journal of the American Society of Nephrology*, *10*(12), 2136–2142. https://doi.org/10.2215/CJN.03640415

Levey, A. S., Stevens, L. A., Schmid, C. H., Iii, A. F. C., Feldman, H. I., Kusek, J. W., Eggers, P., & Coresh, J. (2009). *A New Equation to Estimate Glomerular Filtration Rate*.

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., … Skibelund, A. K. (2021a). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*, *42*(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., … Skibelund, A. K. (2021b). 2021 ESC Guidelines for the diagnosis and treatment of acute and

chronic heart failure. *European Heart Journal*, *42*(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368

Meaney, C. J., Beccari, M. V., Yang, Y., & Zhao, J. (2017). Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *37*(4), 401–411. https://doi.org/10.1002/phar.1906

Montague, B. T., Ouellette, J. R., & Buller, G. K. (2008). Retrospective Review of the Frequency of ECG Changes in Hyperkalemia. *Clinical Journal of the American Society of Nephrology*, *3*(2), 324–330. https://doi.org/10.2215/cjn.04611007

Morimoto, K., Tominaga, Y., Agatsuma, Y., Miyamoto, M., Kashiwagura, S., Takahashi, A., Sano, Y., Yano, K., Kakinuma, C., Ogihara, T., & Tomita, M. (2018). Intestinal secretion of indoxyl sulfate as a possible compensatory excretion pathway in chronic kidney disease. *Biopharmaceutics & Drug Disposition*, *39*(7), 328–334. https://doi.org/10.1002/bdd.2149

Nasir, K., & Ahmad, A. (n.d.). TREATMENT OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A COMPARISON OF CALCIUM POLYSTYRENE SULPHONATE AND SODIUM POLYSTYRENE SULPHONATE. *J Ayub Med Coll Abbottabad*.

Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., Despres, J.-P., Ho, J. E., Joseph, J. J., Kernan, W. N., Khera, A., Kosiborod, M. N., Lekavich, C. L., Lewis, E. F., Lo, K. B., … on behalf of the American Heart Association. (2023). Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circulation*, *148*(20), 1606–1635. https://doi.org/10.1161/CIR.0000000000001184

Nordheim, E., & Geir Jenssen, T. (2021). Chronic kidney disease in patients with diabetes mellitus. *Endocrine Connections*, *10*(5), R151–R159. https://doi.org/10.1530/EC-21-0097

Núñez, J., Bayés-Genís, A., Zannad, F., Rossignol, P., Núñez, E., Bodí, V., Miñana, G., Santas, E., Chorro, F. J., Mollar, A., Carratalá, A., Navarro, J., Górriz, J. L., Lupón, J., Husser, O., Metra, M., & Sanchis, J. (2018). Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality.

*Circulation*, *137*(13), 1320–1330. https://doi.org/10.1161/CIRCULATIONAHA.117.030576

on behalf of the ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group, Vervloet, M. G., Sezer, S., Massy, Z. A., Johansson, L., Cozzolino, M., & Fouque, D. (2017). The role of phosphate in kidney disease. *Nature Reviews Nephrology*, *13*(1), 27–38. https://doi.org/10.1038/nrneph.2016.164

Palmer, B. F. (2020). Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. *Mayo Clinic Proceedings*, *95*(2), 339–354. https://doi.org/10.1016/j.mayocp.2019.05.019

Palmer, B. F., Carrero, J. J., Clegg, D. J., Colbert, G. B., Emmett, M., Fishbane, S., Hain, D. J., Lerma, E., Onuigbo, M., Rastogi, A., Roger, S. D., Spinowitz, B. S., & Weir, M. R. (2021a). Clinical Management of Hyperkalemia. *Mayo Clinic Proceedings*, *96*(3), 744–762. https://doi.org/10.1016/j.mayocp.2020.06.014

Palmer, B. F., Carrero, J. J., Clegg, D. J., Colbert, G. B., Emmett, M., Fishbane, S., Hain, D. J., Lerma, E., Onuigbo, M., Rastogi, A., Roger, S. D., Spinowitz, B. S., & Weir, M. R. (2021b). Clinical Management of Hyperkalemia. *Mayo Clinic Proceedings*, *96*(3), 744–762. https://doi.org/10.1016/j.mayocp.2020.06.014

Palmer, B. F., & Clegg, D. J. (2017). Diagnosis and treatment of hyperkalemia. *Cleveland Clinic Journal of Medicine*, *84*(12), 934–942. https://doi.org/10.3949/ccjm.84a.17056

Palmer, B. F., & Clegg, D. J. (2024). Hyperkalemia treatment standard. *Nephrology Dialysis Transplantation*, *39*(7), 1097–1104. https://doi.org/10.1093/ndt/gfae056

Prevalence and Disease Burden of Chronic Kidney Disease. (2019). In J.-C. Lv & L.-X. Zhang, *Advances in Experimental Medicine and Biology* (pp. 3–15). Springer Singapore. https://doi.org/10.1007/978-981-13-8871-2_1

Raebel, M. A., Ross, C., Xu, S., Roblin, D. W., Cheetham, C., Blanchette, C. M., Saylor, G., & Smith, D. H. (2010). Diabetes and Drug-Associated

Hyperkalemia: Effect of Potassium Monitoring. *Journal of General Internal Medicine*, *25*(4), 326–333. https://doi.org/10.1007/s11606-009-1228-x

Ren, H., Leon, S. J., Whitlock, R., Rigatto, C., Komenda, P., Bohm, C., Collister, D., & Tangri, N. (2022). Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors. *Clinical Kidney Journal*, *15*(9), 1713–1719. https://doi.org/10.1093/ckj/sfac077

Ronco, C., Haapio, M., House, A. A., Anavekar, N., & Bellomo, R. (2008). Cardiorenal Syndrome. *Journal of the American College of Cardiology*, *52*(19), 1527–1539. https://doi.org/10.1016/j.jacc.2008.07.051

Rossignol, P., Lainscak, M., Crespo-Leiro, M. G., Laroche, C., Piepoli, M. F., Filippatos, G., Rosano, G. M. C., Savarese, G., Anker, S. D., Seferovic, P. M., Ruschitzka, F., Coats, A. J. S., Mebazaa, A., McDonagh, T., Sahuquillo, A., Penco, M., Maggioni, A. P., Lund, L. H., & Heart Failure Long-Term Registry Investigators Group. (2020). Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. *European Journal of Heart Failure*, *22*(8), 1378–1389. https://doi.org/10.1002/ejhf.1793

Seliger, S. L. (2019). Hyperkalemia in patients with chronic renal failure. *Nephrology Dialysis Transplantation*, *34*(Supplement_3), iii12–iii18. https://doi.org/10.1093/ndt/gfz231

Sevamontree, C., Jintajirapan, S., Phakdeekitcharoen, P., & Phakdeekitcharoen, B. (2024). The Prevalence and Risk Factors of Hyperkalemia in the Outpatient Setting. *International Journal of Nephrology*, *2024*, 1–9. https://doi.org/10.1155/2024/5694131

Shin, D. H., Lee, M. J., Kim, S. J., Oh, H. J., Kim, H. R., Han, J. H., Koo, H. M., Doh, F. M., Park, J. T., Han, S. H., Yoo, T.-H., & Kang, S.-W. (2012). Preservation of Renal Function by Thyroid Hormone Replacement Therapy in Chronic Kidney Disease Patients with Subclinical Hypothyroidism. *The Journal of Clinical Endocrinology & Metabolism*, *97*(8), 2732–2740. https://doi.org/10.1210/jc.2012-1663

*Subramonian & Frey, 2020*. (n.d.).

Sun, J., Liu, Q., Seery, S., Sun, L., Yuan, Y., Wang, W., Wang, Y., Cui, Z., Wang, Y., Wang, Y., Zhu, J., Zhang, M., Lai, Y., & Jin, K. (2024). The impact of hyperkalemia on ICU admission and mortality: A retrospective study of Chinese emergency department data. *BMC Emergency Medicine*, *24*(1), 95. https://doi.org/10.1186/s12873-024-01011-z

Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018). Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. *Toxins*, *10*(1), 33. https://doi.org/10.3390/toxins10010033

Vidal, H., Salgado, V., Alves, P., Fonseca1, N. M., Frochot, V., & Ferreira, A. (2024). Calcium polystyrene sulfonate–induced colitis: Advanced characterization of crystal nature with infrared spectroscopy. *Clinical Kidney Journal*, *17*(8). https://doi.org/10.1093/ckj/sfae210

Wang, X., Chen, D., Song, X., Wang, J., & Zhang, H. (2023). Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: A single-center randomized controlled trial. *Journal of International Medical Research*, *51*(4). https://doi.org/10.1177/03000605231167516

Watanabe, R. (2020). Hyperkalemia in chronic kidney disease. *Revista Da Associação Médica Brasileira*, *66*(suppl 1), s31–s36. https://doi.org/10.1590/1806-9282.66.s1.31

Watson, M. A., Baker, T. P., Nguyen, A., Sebastianelli, M. E., Stewart, H. L., Oliver, D. K., Abbott, K. C., & Yuan, C. M. (2012a). Association of Prescription of Oral Sodium Polystyrene Sulfonate With Sorbitol in an Inpatient Setting With Colonic Necrosis: A Retrospective Cohort Study. *American Journal of Kidney Diseases*, *60*(3), 409–416. https://doi.org/10.1053/j.ajkd.2012.04.023

Watson, M. A., Baker, T. P., Nguyen, A., Sebastianelli, M. E., Stewart, H. L., Oliver, D. K., Abbott, K. C., & Yuan, C. M. (2012b). Association of Prescription of Oral Sodium Polystyrene Sulfonate With Sorbitol in an Inpatient Setting With Colonic Necrosis: A Retrospective Cohort Study. *American Journal of Kidney Diseases*, *60*(3), 409–416. https://doi.org/10.1053/j.ajkd.2012.04.023

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic Kidney Disease. *The Lancet*, *389*(10075), 1238–1252. https://doi.org/10.1016/s0140-6736(16)32064-5

Weir, M. R., & Rolfe, M. (2010). Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. *Clinical Journal of the American Society of Nephrology*, *5*(3), 531–548. https://doi.org/10.2215/CJN.07821109

Yu, M.-Y., Yeo, J. H., Park, J.-S., Lee, C. H., & Kim, G.-H. (2017). Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. *PLOS ONE*, *12*(3), e0173542. https://doi.org/10.1371/journal.pone.0173542

Zhang, S., Zhang, G., Huang, P., Ren, Y., Lin, B., Shao, Y., & Ye, X. (2023). Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions. *BMC Geriatrics*, *23*(1), 849. https://doi.org/10.1186/s12877-023-04557-y